Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 814.85M P/E - EPS this Y -14.20% Ern Qtrly Grth -
Income -107.85M Forward P/E -6.69 EPS next Y -8.60% 50D Avg Chg 33.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 56.00%
Dividend N/A Price/Book 5.17 EPS next 5Y - 52W High Chg -21.00%
Recommedations 1.80 Quick Ratio 20.98 Shares Outstanding 54.83M 52W Low Chg 254.00%
Insider Own 7.85% ROA -24.74% Shares Float 40.20M Beta 0.99
Inst Own 108.17% ROE -46.05% Shares Shorted/Prior 6.46M/6.08M Price 18.41
Gross Margin - Profit Margin - Avg. Volume 701,819 Target Price 57.70
Oper. Margin - Earnings Date Aug 8 Volume 377,642 Change -3.51%
About Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics, Inc. News
11/18/24 Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
11/11/24 Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/11/24 Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet
11/11/24 Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
11/08/24 Vera Therapeutics to Participate at Upcoming Investor Conferences
11/07/24 Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
10/29/24 Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
10/29/24 Vera Therapeutics price target raised to $64 from $56 at Guggenheim
10/28/24 Vera Therapeutics Breaks Out On Promising Results For Kidney Drug
10/28/24 Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
10/28/24 Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
10/26/24 Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
10/02/24 Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
10/02/24 Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
09/26/24 Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024?
09/16/24 Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
09/12/24 Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
09/05/24 Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now
09/03/24 Adobe and 2 More Stocks Added to JP Morgan Focus List. Here’s Why.
08/29/24 Vera Therapeutics to Participate at September Investor Conferences
VERA Chatroom

User Image cuttail07 Posted - 15 hours ago

$VERA https://youtu.be/TzuodJ39DwA?si=Wo6vdew-YcbUtEAn

User Image FetchDog Posted - 2 days ago

$ETNB Looks like a higher low was achieved today (relative to yesterday's low). So if this makes a higher high by rising above $8.02, the price should start an uptrend. The pattern of 1) good news with a price rise, 2) offering with a price drop and finally 3) price recovery is a fairly reliable pattern, especially when the stock is a "quality" stock that institutions like to own. For example, look at what happened to $VERA recently. Of course, no guaranties, just probabilities. I entered ETNB long today.

User Image cuttail07 Posted - 2 days ago

$VERA Likely to be first out of the gate in 2026 with commercial launch of Atacicept for dual APRIL/BAFF antagonist. Recently strengthened balance sheet with 700 million cash on hand and quarterly 50 million burn rate. They are an appealing buyout candidate. Closest competitor was bought out by VRTX for 4.9 billion. There is a compelling case to be made for owning the shares here with top line data readout expected H2 2025. It’s on my list to begin DCA at pricing <40/share.

User Image Doozio Posted - 1 week ago

Textbook $$$ patterns look $vera possible in da FUTUre of 🧠⏰ just $axsm body this weekend INTA 🧠⏰♾️

User Image bigkahunatrader Posted - 1 week ago

$VERA Vera Therapeutics, Inc. CAT-3 TM-7 Cycle Trade...excellent cycle squeeze coming in...watching this closely... https://youtu.be/pz8uassZ6_k

User Image FetchDog Posted - 2 weeks ago

$VERA Closing my swing trade (predictable bounce). Nice profits.

User Image FlynancialAnalyst Posted - 2 weeks ago

$VERA green on the week is green on the week! $40 defended and that volume is noteworthy VERA glad to have been able to position here on the Wed. weakness. #ShortSqueeze underway. $80 in time. $TWST too

User Image FlynancialAnalyst Posted - 2 weeks ago

Let's get a $VERA special weekly close $IWM

User Image FetchDog Posted - 10/31/24

$VERA In for a swing trade. Great future here for long term investors as well. Typical pattern: stock jumps on important positive news, offering/dilution, stock drops modestly below the offering price, and finally a slow recovery of the stock price. Observe that the good biotech's (such as VERA) raise money before their cash gets very low, i.e. when they are not desparate for funds. Besides being prudent, it prevents a continuous downslide in the stock price when investor's begin to worry about running out of cash and a possible dilution.

User Image FlynancialAnalyst Posted - 10/30/24

$VERA long here on the weekly gap fill, see the weekly close... loved it heading into the week, gotta take a shot

User Image DonCorleone77 Posted - 10/29/24

$VERA Vera Therapeutics 7.14M share Secondary priced at $42.00 The deal priced below last closing price of $42.97. JPMorgan, Goldman Sachs and Evercore ISI are acting as joint book running managers for the offering.

User Image AlertsAndNews Posted - 10/29/24

$VERA Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock "today announced the pricing of an underwritten public offering of 7,142,858 shares of its Class A common stock at a price to the public of $42.00 per share."

User Image OpenOutcrier Posted - 10/29/24

$VERA (-2.8% pre) Vera Therapeutics Inc. (VERA) Announces Proposed $300M Share Offering https://ooc.bz/l/46118

User Image ReaLiLJ Posted - 10/28/24

$HCTI on watch for breakout!! This along with others went bonkers today: $DJT $GLUE $GNLN $VERA #WW

User Image jeffmeredith Posted - 10/28/24

$VERA Totally missed that this went above $50 today. My Oct 24 $40.05 buy sold at $44.51. Just saw the offering announcement, keeping this on watch.

User Image DonCorleone77 Posted - 10/28/24

$VERA Vera Therapeutics announces $300M offering of Class A common stock Vera Therapeutics announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $300M of shares of its Class A common stock. All of the shares are being offered by Vera. J.P. Morgan, Goldman Sachs & Co., Evercore ISI and Cantor are acting as joint book-running managers for the proposed offering.

User Image Doozio Posted - 10/28/24

$VERA bullish wen XBI IWM join in HRMY during 🧠⏰♾️

User Image dragonsfly_ Posted - 10/28/24

$VERA https://markets.businessinsider.com/news/stocks/promising-clinical-data-and-strong-financials-justify-buy-rating-for-vera-therapeutics-amid-atacicept-s-potential-in-igan-1033896844

User Image Subhak Posted - 10/28/24

$VERA fantastic news, sky is the limit!!

User Image Emoz79 Posted - 10/28/24

$VERA Still on big sale!!! Market dont understand from yesterday😂

User Image Datastep Posted - 10/28/24

$VERA Boom! Nice!

User Image GetVector Posted - 10/28/24

Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $PRCT, $VERA.

User Image Charlestrader777 Posted - 10/28/24

$VERA 👀

User Image OpenOutcrier Posted - 10/28/24

$VERA (+11.7% pre) Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 https://ooc.bz/l/45935

User Image dragonsfly_ Posted - 10/27/24

$VERA https://ir.veratx.com/static-files/42477c99-8a06-4547-8967-e73947b4efbd Wow.

User Image FlynancialAnalyst Posted - 10/26/24

$VERA idk about this data but I am quite certain stock going up big time without me on Monday

User Image Camier Posted - 10/26/24

$VERA What do you think of this data?

User Image FlynancialAnalyst Posted - 10/26/24

$JANX this one is $VERA special! Just keeps swimming in spite of $XBI chop, 3rd accumulation wk in a row DD ^^ unchanged

User Image insiderbuyingselling Posted - 10/26/24

$VERA new insider selling: 19375 shares. http://insiderbuyingselling.com/?t=VERA

User Image FlynancialAnalyst Posted - 10/25/24

$VERA high conviction $XBI setup heading into next week. Risk against distribution wk under $40, rising 10/40 wk SMAs. Nice end to the week

Analyst Ratings
Cantor Fitzgerald Overweight Oct 1, 24
Cantor Fitzgerald Overweight Sep 23, 24
Cantor Fitzgerald Overweight Sep 16, 24
Cantor Fitzgerald Overweight Sep 9, 24
Cantor Fitzgerald Overweight Sep 6, 24
JP Morgan Overweight Sep 3, 24
JP Morgan Overweight Aug 13, 24
JP Morgan Overweight May 31, 24
Raymond James Strong Buy May 10, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Katabi Maha Director Director Jan 30 Buy 31.00 161,290 4,999,990 3,628,446 02/01/24
COMMODORE CAPITAL LP 10% Owner 10% Owner Jan 10 Sell 18.00 1,050,000 18,900,000 4,400,000 01/12/24
Fordyce Marshall President and CEO President and CEO Dec 29 Option 2.61 13,516 35,277 256,877 01/03/24
Lin Celia Chief Medical Office.. Chief Medical Officer Aug 21 Sell 16.6547 1,490 24,816 11,010 08/23/23
Curley Joanne Chief Development Of.. Chief Development Officer Aug 21 Sell 16.6558 1,490 24,817 26,962 08/23/23
Fordyce Marshall President and CEO President and CEO Aug 21 Sell 16.6562 5,210 86,779 243,361 08/23/23
SEIDENBERG BETH C Director Director Feb 13 Buy 7.1972 10,072 72,490 1,664,702 02/15/23
SEIDENBERG BETH C Director Director Feb 09 Buy 7.25 400 2,900 1,654,630 02/13/23
Longitude Capital Partners IV,... 10% Owner 10% Owner Feb 06 Buy 7.00 1,714,285 11,999,995 1,714,285 02/08/23
ENRIGHT PATRICK G Director Director Feb 06 Buy 7.00 1,714,285 11,999,995 1,714,285 02/08/23
Sofinnova Venture Partners X,... 10% Owner 10% Owner Feb 06 Buy 7.00 285,714 1,999,998 3,467,156 02/08/23
Curley Joanne Chief Development Of.. Chief Development Officer Nov 09 Sell 16.54 494 8,171 27,315 11/10/22
Curley Joanne Chief Development Of.. Chief Development Officer Oct 18 Option 7.82 8,590 67,174 27,811 10/20/22
Curley Joanne Chief Development Of.. Chief Development Officer Oct 18 Sell 19.63 8,590 168,622 27,809 10/20/22
Fordyce Marshall President and CEO President and CEO Sep 07 Option 2.9 21,891 63,484 196,256 09/09/22
Fordyce Marshall President and CEO President and CEO Sep 07 Sell 20.28 21,891 443,949 181,150 09/09/22
Carlyle Group Inc. 10% Owner 10% Owner Aug 17 Option 11 9,925 109,175 2,970,156 08/19/22
Carlyle Group Inc. 10% Owner 10% Owner Aug 17 Sell 20.46 9,925 203,066 2,960,231 08/19/22
Fordyce Marshall President and CEO President and CEO Aug 12 Option 2.9 20,528 59,531 157,928 08/15/22
Fordyce Marshall President and CEO President and CEO Aug 12 Sell 20.16 20,528 413,844 137,400 08/15/22
Curley Joanne Chief Development Of.. Chief Development Officer Jul 19 Option 4.63 11,444 52,986 18,281 07/20/22
Curley Joanne Chief Development Of.. Chief Development Officer Jul 19 Sell 16.28 11,444 186,308 18,273 07/20/22
Curley Joanne Chief Development Of.. Chief Development Officer Jun 22 Option 6.37 1,239 7,892 25,233 06/23/22
Curley Joanne Chief Development Of.. Chief Development Officer Jun 22 Sell 15.02 1,545 23,206 23,688 06/23/22
Curley Joanne Chief Development Of.. Chief Development Officer Jun 17 Option 4.63 4,687 21,701 28,535 06/21/22
Curley Joanne Chief Development Of.. Chief Development Officer Jun 17 Sell 15.05 5,887 88,599 23,994 06/21/22
Longitude Capital Partners IV,... 10% Owner 10% Owner Feb 10 Buy 15.00 333,333 4,999,995 3,429,927 04/05/22
ENRIGHT PATRICK G Director Director Feb 10 Buy 15.00 333,333 4,999,995 3,429,927 04/05/22
Sofinnova Venture Partners X,... 10% Owner 10% Owner Feb 10 Buy 15 266,666 3,999,990 3,181,442 02/14/22